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EIMSAbstract 1,3,4-Oxadiazole bearing compounds are one of the most attractive class for researchers
due to their biological activities. In the undertaken research, a number of N-substituted derivatives
of 2-(5-(1-(phenylsulfonyl)piperidin-4-yl)-1,3,4-oxadiazol-2-ylthio)acetamide (6a–n) were synthe-
sized through a series of steps. The reaction of benzenesulfonyl chloride with ethyl isonipecotate
yielded ethyl 1-(phenylsulfonyl)piperidin-4-carboxylate (1), which was further converted into
1-(phenylsulfonyl)piperidin-4-carbohydrazide (2) and 5-(1-(phenylsulfonyl)piperidin-4-yl)-1,3,4-
oxadiazol-2-thiol (3) respectively. The target compounds 6a–n were synthesized by the reaction
of compound 3 with different N-aralkyl/aryl substituted 2-bromoacetamides (5a–n) in the presence
of a weak base and polar aprotic solvent. The structures of the synthesized compounds were eluci-
dated through 1H-NMR, IR and mass spectral data. The synthesized compounds were screened
against Gram-negative and Gram-positive bacteria and exhibited moderate to talented activity.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The synthesis of the poly-functional compounds has been esca-
lating these days. Acetamide linkage is found to be active in
many important drugs and there are varieties of bioactive acet-
amide derivatives which have been developed in recent years.
Acetamide are found to be potential agents for anthelmintic
(Sawant and Kawade, 2011), anticonvulsant (Jawed et al.,
S616 H. Khalid et al.2010), antioxidant, anti-inﬂammatory (Autore et al., 2010;
Ayhan-Kılcıgil et al., 2012), anti-arthritic, anticancer, anti
bacterial and antifungal activities (Kidwai et al., 2002;
Kanagarajan et al., 2010). A series of glycosyl thio acetamide
and glycosyl sulfonyl acetamide derivatives was evaluated for
antitubercular activity (Ghosh et al., 2008).
The present work is the poly-functional synthesis having sul-
fonamide, piperidine, 1,3,4-oxadiaozole and acetamide moiety
together in one molecule in continuation of our previously re-
ported work (Khalid et al., 2012). It was speculated that the
2,5-disubstituted 1,3,4-oxadiazol ring along with the potential
piperidine ring moiety will boost the activity of the molecule.
The synthesis was performed through the intermolecular
cyclization of 1-(phenylsulfonyl)piperidin-4-carbohydrazide to
5-(1-(phenylsulfonyl)piperidin-4-yl)-1,3,4-oxadiazol-2-thiol
and ﬁnally to the N-aryl/aralkyl substituted-2-(5-(1-(phenylsul-
fonyl)piperidin-4-yl)-1,3,4-oxadiazol-2-ylthio) acetamide prod-
ucts. Further, in vitro antibacterial screening of all the
synthesized compounds 6a–n against clinically isolated
Gram-negative (Salmonellatyphi, Escherichia coli andKlebsiella
pneumonae) and Gram-positive bacteria (Bacillus subtilis and
Staphylococcus aureus) using standard procedure was done
and it was observed that the different electrophilic substitution
inﬂuenced the antibacterial activity signiﬁcantly frommoderate
to excellent level.
2. Experimental
2.1. General
Melting points of the synthesized compounds were recorded
on a Grifﬁn and George melting point apparatus by open cap-
illary tube and were uncorrected. Thin layer chromatography
(TLC) on pre-coated silica gel G-25-UV254 plates was used
to observe the reaction progress along with different polarity
solvent systems using ethyl acetate and n-hexane. Identiﬁcation
of spots was carried out at 254 nm UV Lamp, and by ceric
sulfate reagent. The IR spectra were recorded in KBr pellet
method on a Jasco-320-A spectrophotometer (wave number
in cm1). Nuclear magnetic resonance spectra were recorded
in CDCl3 on a Bruker spectrometer operating at 300 and
400 MHz. Chemical shifts are given in ppm. Mass spectra
(EIMS) were recorded on a JMS-HX-110 spectrometer with
a data system.
2.2. Preparation of ethyl 1-(phenylsulfonyl)piperidin-4-
carboxylate in aqueous media (1)
Ethyl isonipecotate (a; 20.0 mL, 10.0 mmol) was suspended in
50 mL water and along with pH control at 9.0 by the addition
of aqueous solution of Na2CO3 (5%) at 0–5 C. Benzenesulfo-
nyl chloride (b; 29.0 mL, 10.0 mmol) was added to the reaction
mass slowly over 10–15 min. After that, the temperature of the
reaction mixture was allowed to rise slowly to 30 C (RT). The
reaction mixture was stirred for 3–4 h and monitored by TLC
for the completion of reaction. At the end of reaction, conc.
HCl (2 mL, 11 M) was added slowly to adjust the pH to 2.0.
The precipitates appeared after a stay of 5–10 min. The precip-
itates were ﬁltered and washed with distilled water to afford
the title compound 1 on drying. White amorphous powder;Yield: 90%; m.p. 60–62 C; Molecular formula: C14H19NO4S;
molecular weight: 297 gmol1; IR (KBr, cm1) vmax: 3015 (Ar-
H), 2925 (–CH2 stretching), 1760 (O–C‚O ester stretching),
1531 (Ar C‚C stretching), 1329 (–SO2 stretching);
1H-NMR
(300 MHz, CDCl3, d/ppm): 7.78 (dd, J = 7.8, 1.8 Hz, 2H, H-
20 and H-6’), 7.68–7.63 (m, 1H, H-40), 7.62 (dd, J= 7.5,
1.8 Hz, 2H, H-30 and H-50), 4.11 (q, J = 7.2 Hz, 2H, O–
CH2CH3), 3.64 (t, J= 3.6 Hz, 2H, Heq-2 and Heq-6), 3.59 (t,
J= 3.6 Hz, 2H, Hax-2 and Hax-6), 2.13–2.00 (m, 1H, H-4),
1.75–1.70 (m, 4H, H-3 and H-5), 1.20 (t, J = 6.9 Hz, 3H, O–
CH2CH3); EIMS (m/z): 297 [M]
+, 224 [C11H14NO2S]
+, 141
[C6H5O2S]
+, 82 [C5H8N]
.+, 77 [C6H5]
+.
2.3. Preparation of 1-(phenylsulfonyl)piperidin-4-
carbohydrazide (2)
Ethyl-1-(phenylsulfonyl)piperidin-4-carboxylate (1; 0.03 mol,
10 g) and 50 mL of methanol were added in the round bottom
ﬂask and the mixture was cooled to 0–5 C. Hydrazine hydrate
(80%, 30 mL) was added drop wise to the reaction mixture fol-
lowed by stirring for 5–6 h at 0–5 C. Reaction completion was
monitored by TLC. At the end of reaction excess solvent was
removed by distillation to afford white crystalline product
which was ﬁltered off and washed with n-hexane. White Crys-
tals; Yield: 80%; m.p. 119–121 C; Molecular formula:
C12H17N3O3S; molecular weight: 283 gmol
1; IR (KBr,
cm1) vmax: 3310 (N-H stretching), 3018 (Ar-H), 1630 (C‚O
stretching), 1529 (Ar C‚C stretching), 1325 (–SO2 stretching);
1H-NMR (300 MHz, CDCl3, d/ppm): 7.85 (s, NH-CO), 7.78
(dd, J = 7.8, 1.8 Hz, 2H, H-20 and H-60), 7.66–7.63 (m, 3H,
H-30 to H-50), 3.79 (t, J= 3.6 Hz, 2H, Heq-2 and Heq-6),
3.75 (t, J= 3.6 Hz, 2H, Hax-2 and Hax-6), 2.12–1.99 (m, 1H,
H-4), 1.79–1.75 (m, 4H, H-3 and H-5); EIMS (m/z): 283
[M]+, 252 [C12H14NO3S]
+, 224 [C11H14NO2S]
+, 141
[C6H5O2S]
+, 82 [C5H8N]
+, 77 [C6H5]
+.
2.4. Preparation of 5-(1-(phenylsulfonyl)piperidin-4-yl)-1,3,4-
oxadiazol-2-thiol (3)
Carbohydrazide (2; 8.0 g, 0.028 mol) was dissolved in abso-
lute ethanol (30 mL) in a 500 mL round bottom ﬂask. Car-
bon disulﬁde (12.0 mL, 0.15 mol) was then added to the
solution followed by excess potassium hydroxide (4.0 g,
0.88 mol). This reaction mixture was properly stirred and re-
ﬂuxed for 6 h. Color of solution was changed from yellow to
milky with the progress of reaction. The mixture was diluted
with distilled water (50 mL) and acidiﬁed with dilute hydro-
chloric acid to pH 2–3. The formed precipitates were ﬁltered,
washed with water and re-crystallized from ethanol. White
powder; Yield: 88%; m.p. 210–213 C; Molecular formula:
C13H15N3O3S2; molecular weight: 325 gmol
1; IR (KBr,
cm1) vmax: 3035 (Ar-H), 2250 (S-H stretching), 1593
(C‚N stretching), 1527 (Ar C‚C stretching), 1326 (-SO2
stretching); 1H-NMR (300 MHz, CDCl3, d/ppm): 7.80 (dd,
J = 7.8, 1.8 Hz, 2H, H-200and H-600), 7.67–7.65 (m, 3H,
H-300 to 500), 3.75 (t, J= 3.6 Hz, 2H, Heq-20 and Heq-60),
3.71 (t, J= 3.6 Hz, 2H, Hax-2
0 and Hax-60), 2.80–2.75 (m,
1H, H-40), 1.80–1.76 (m, 4H, H-30 and H-50); EIMS (m/z):
325 [M]+, 252 [C12H14NO3S]
+, 224 [C11H14NO2S]
+, 141
[C6H5O2S]
+, 82 [C5H8N]
.+, 77 [C6H5]
+.
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The calculated amount of substituted aralkyl/aryl amines
(4a–n, 11.0 mmoles) were dispersed in 10 mL distilled water
in an iodine ﬂask containing 5% Na2CO3 solution to adjust
the pH of 8.0 to 9.0. The reaction mass was stirred for
10 min at 0–5 C and then bromoacetyl bromide (1.0 mL;
11.0 mmoles) was poured into the reaction mass drop wise
in 2–5 min at 0–5 C. After that the iodine ﬂask was shaken
robustly till the formation of solid precipitates and the
temperature was raised to room temperature (30 C). The
solid precipitates were further stirred for 45 min. The reac-
tion progress was monitored by TLC (n-hexane:ethyl acetate;
70:30). At the end of reaction, the obtained solids were
ﬁltered, washed with distilled water and dried to yield the
corresponding electrophiles, N-aralkyl/aryl-substituted-2-
bromoacetamide (5a–n).
2.6. General procedure for the synthesis of compounds 6a–n
5-(1-(Phenylsulfonyl)piperidin-4-yl)-1,3,4-oxadiazol-2-thiol (3,
0.032 g, 0.1 mmol) was dissolved in N,N-dimethyl formamide
(DMF, 10 mL) in a round bottom ﬂask (50 mL) followed by
the addition of sodium hydride (0.002 g, 0.1 mmol) to the
mixture. The mixture was stirred for 30 min at room temper-
ature (30 C) and then the electrophiles 5a–n were added
slowly to the mixture with further stirring for 2–3 h. The
progress of reaction was monitored via TLC till single spot.
Distilled water was added to the ﬂask and the products were
recovered by ﬁltration or solvent extraction according to the
product nature.
2.6.1. N-(2,3-dimethylphenyl)-2-(5-(1-
(phenylsulfonyl)piperidin-4-yl)-1,3,4-oxadiazol-2-ylthio)
acetamide (6a)
White shiny scales; Yield: 73%; m.p. 112–114 C; Molecular
formula: C23H26N4O4S2; molecular weight: 486 gmol
1; IR
(KBr, cm1) vmax: 3431 (N–H stretching), 3026 (Ar–H), 2887
(–CH2 stretching), 1623 (C‚N stretching), 1575 (Ar C‚C
stretching), 1327 (–SO2 stretching);
1H-NMR (300 MHz,
CDCl3, d/ppm): 8.66 (s, 1H, CONH), 7.77 (dd, J= 1.2,
6.9 Hz, 2H, H-200 and H-600), 7.59-7.57 (m, 3H, H-300 to H-
500), 7.55 (d, J= 7.8 Hz, 1H, H-600 0), 7.06 (t, J= 7.8 Hz, 1H,
H-500 0), 6.99 (d, J= 7.5 Hz, 1H, H-400 0), 3.97 (s, 2H, S-CH2),
3.77 (t, J= 3.6 Hz, 2H, Heq-2
0 and Heq-60), 2.89-2.80 (m,
1H, H-40), 2.56 (dt, J= 2.7, 9.0 Hz, 2H, Hax-20 and Hax-60),
2.26 (s, 3H, CH3-2
00 0), 2.09 (s, 3H, CH3-300 0), 2.02-1.89 (m,
4H, H-30 and H-50); EIMS (m/z): 486 [M]+, 252
[C12H14NO3S]
+, 224 [C11H14NO2S]
+, 141 [C6H5O2S]
+, 105
[C8H9]
+, 82 [C5H8N]
+, 77 [C6H5]
+.
2.6.2. N-(2-methylphenyl)-2-(5-(1-(phenylsulfonyl)piperidin-4-
yl)-1,3,4-oxadiazol-2-ylthio) acetamide (6b)
Colorless crystals; Yield: 78%;m.p. 118 C;Molecular formula:
C22H24N4O4S2; molecular weight: 472 gmol
1; IR (KBr, cm1)
vmax: 3443 (N–H stretching), 3034 (Ar–H), 2918 (–CH2 stretch-
ing), 1597 (C‚Nstretching), 1567 (ArC‚C stretching), 1330 (–
SO2 stretching);
1H-NMR (300 MHz, CDCl3, d/ppm): 8.74 (s,
1H, CONH), 7.75 (d, J= 7.5 Hz, 2H, H-200 and H-600), 7.61-
7.58 (m, 3H, H-300 to H-500), 7.57-7.49 (m, 4H, H-300 0 to H-600 0),3.96 (s, 2H, S-CH2), 3.72 (t, J= 5.4 Hz, 2H, Heq-2
0 and Heq-
60), 2.89-2.82 (m, 1H, H-40), 2.58 (t, J= 2.7, 5.4 Hz, 2H, Hax-
20 and Hax-60), 2.20 (s, 3H, CH3-200 0), 2.15-1.91 (m, 4H, H-30
and H-50); EIMS (m/z): 472 [M]+, 252 [C12H14NO3S]
+, 224
[C11H14NO2S]
+, 141 [C6H5O2S]
+, 91 [C7H7]
+, 82 [C5H8N]
+,
77 [C6H5]
+, 51 [C4H3]
+.2.6.3. N-(3-methylphenyl)-2-(5-(1-(phenylsulfonyl)piperidin-4-
yl)-1,3,4-oxadiazol-2-ylthio) acetamide (6c)
White crystalline solid; Yield: 77%; m.p. 116–118 C; Molecu-
lar formula: C22H24N4O4S2; molecular weight: 472 gmol
1; IR
(KBr, cm1) vmax: 3440 (N–H stretching), 3035 (Ar–H), 2916
(–CH2 stretching), 1599 (C‚N stretching), 1566 (Ar C‚C
stretching), 1328 (–SO2 stretching);
1H-NMR (300 MHz,
CDCl3, d/ppm): 8.97 (s, 1H, CONH), 7.77 (dd, J= 1.5,
6.9 Hz, 2H, H-200 and H-600), 7.60-7.57 (m, 3H H-300 to H-500),
7.33 (s, 1H, H-200 0), 7.49 (dd, J= 1.5, 7.5 Hz, 1H, H-600 0),
7.16 (t, J = 7.8 Hz, 1H, H-500 0), 6.92 (d, J = 7.5 Hz, 1H, H-
400 0), 3.90 (s, 2H, S-CH2), 3.77 (t, J= 5.4 Hz, 2H, Heq-20 and
Heq-6
0), 2.90-2.80 (m, 1H, H-40), 2.59 (dt, J= 2.7, 12.0 Hz,
2H, Hax-2
0 and Hax-60), 2.13 (s, 3H, CH3-300 0), 2.16-1.90 (m,
4H, H-30 and H-50); EIMS (m/z): 472 [M]+, 252
[C12H14NO3S]
+, 224 [C11H14NO2S]
+, 141 [C6H5O2S]
+, 91
[C7H7]
+, 82 [C5H8N]
+, 77 [C6H5]
+, 51 [C4H3]
+.2.6.4. N-(4-methylphenyl)-2-(5-(1-(phenylsulfonyl)piperidin-4-
yl)-1,3,4-oxadiazol-2-ylthio) acetamide (6d)
White powder; Yield: 78%; m.p. 119–121 C; Molecular for-
mula: C22H24N4O4S2; molecular weight: 472 gmol
1; IR
(KBr, cm1) vmax: 3439 (N–H stretching), 3028 (Ar–H), 2920
(–CH2 stretching), 1620 (C‚N stretching), 1579 (Ar C‚C
stretching), 1330 (–SO2 stretching);
1H-NMR (300 MHz,
CDCl3, d/ppm): 8.95 (s, 1H, CONH), 7.77 (dd, J= 1.5,
7.2 Hz, 2H, H-200 and H-600), 7.60-7.57 (m, 3H, H-300 to H-
500), 7.38 (d, J = 8.4 Hz, 2H, H-200 0 and H-600 0), 7.10 (d,
J = 8.1 Hz, 2H, H-300 0 and H-500 0), 3.90 (s, 2H, S-CH2), 3.76
(t, J= 3.6 Hz, 2H, Heq-2
0 and Heq-60), 2.88-2.80 (m, 1H, H-
40), 2.59 (dt, J= 3.0, 8.7 Hz, 2H, Hax-20 and Hax-60), 2.28 (s,
3H, CH3-4
00 0), 2.16-1.90 (m, 4H, H-30 and H-50); EIMS (m/z):
472 [M]+, 252 [C12H14NO3S]
+, 224 [C11H14NO2S]
+, 141
[C6H5O2S]
+, 91 [C7H7]
+, 82 [C5H8N]
+, 77 [C6H5]
+, 51
[C4H3]
+.2.6.5. N-(2-methoxyphenyl)-2-(5-(1-(phenylsulfonyl)piperidin-
4-yl)-1,3,4-oxadiazol-2-ylthio) acetamide (6e)
Off-white needle crystals; Yield: 88%; m.p. 106 C; Molecular
formula: C22H24N4O5S2; molecular weight: 488 gmol
1; IR
(KBr, cm1) vmax: 3042 (Ar–H), 1610 (C‚N stretching),
1569 (Ar C‚C stretching), 1330 (–SO2 stretching);
1H-
NMR (400 MHz, CDCl3, d/ppm): 9.05 (s, 1H, CONH),
8.28 (d, J= 8.0 Hz, 1H, H-600 0), 7.76 (d, J= 7.6 Hz, 2H,
H-200 and H-600), 7.59-7.50 (m, 3H, H-300 to H-500), 7.03 (t,
J= 7.2 Hz, 1H, H-400 0), 6.92 (t, J= 7.6 Hz, 1H, H-500 0),
6.84 (t, J= 8.0 Hz, 1H, H-300 0), 4.01 (s, 2H, S-CH2), 3.82
(s, 3H, CH3O-2
00 0), 3.72 (t, J= 5.6 Hz, 2H, Heq-20 and Heq-
60), 2.84-2.82 (m, 1H, H-40), 2.58 (t, J= 5.6 Hz, 2H, Hax-20
and Hax-6
0), 2.13-1.94 (m, 4H, H-30 and H-50); EIMS (m/z):
488 [M]+, 252 [C12H14NO3S]
+, 224 [C11H14NO2S]
+, 141
[C6H5O2S]
+, 107 [C7H7O]
+, 82 [C5H8N]
+, 77 [C6H5]
+.
S618 H. Khalid et al.2.6.6. N-(3-methoxyphenyl)-2-(5-(1-(phenylsulfonyl)piperidin-
4-yl)-1,3,4-oxadiazol-2-ylthio) acetamide (6f)
Rust sticky solid; Yield: 82%; Molecular formula:
C22H24N4O5S2; molecular weight: 488 gmol
1; IR (KBr,
cm1): vmax: 3032 (Ar–H), 1614 (C‚N stretching), 1515 (Ar
C‚C stretching), 1326 (–SO2 stretching);
1H-NMR
(300 MHz, CDCl3, d/ppm): 7.81 (dd, J= 1.8, 7.5 Hz, 2H, H-
200 and H-600), 7.73 (s, 1H, H-200 0), 7.64-7.59 (m, 3H, H-300 to
H-500), 7.56-7.47 (m, 2H, H-500 0 and H-600 0), 6.69-6.59 (m, 3H,
H-4000), 3.96 (s, 2H, S-CH2), 3.76 (s, 3H, CH3O-300 0), 3.68 (t,
J= 5.4 Hz, 2H, Heq-2
0 and Heq-60), 3.55 (t, J= 5.4 Hz, 2H,
Hax-2
0 and Hax-60), 2.85-2.79 (m, 1H, H-40), 2.00-1.87 (m,
4H, H-30 and H-50); EIMS (m/z): 488 [M]+, 252
[C12H14NO3S]
+, 224 [C11H14NO2S]
+, 141 [C6H5O2S]
+, 107
[C7H7O]
+, 82 [C5H8N]
+, 77 [C6H5]
+.
2.6.7. N-(2-methoxycarbonylphenyl)-2-(5-(1-
(phenylsulfonyl)piperidin-4-yl)-1,3,4-oxadiazol-2-
ylthio)acetamide (6g)
White powder; Yield: 76%; m.p. 162–165 C; Molecular for-
mula: C23H24N4O5S2; molecular weight: 500 gmol
1; IR
(KBr, cm1): vmax: 3035 (Ar–H), 1616 (C‚N stretching),
1555 (Ar C‚C stretching), 1319 (–SO2 stretching);
1H-NMR
(400 MHz, CDCl3, d/ppm): 8.63 (d, J= 8.0 Hz, 1H, H-600 0),
8.01 (d, J= 8.0 Hz, 1H, H-300 0), 7.75 (d, J= 6.8 Hz, 2H,
H-200 and H-600), 7.58-7.50 (m, 4H, H-300 to H-500, H-500 0),
7.12-7.09 (m, 1H, H-400 0), 4.11 (s, 2H, S-CH2), 3.91 (s, 3H,
COOCH3-2
00 0), 3.72 (m, 2H, Heq-20 and Heq-60), 3.67 (m, 2H,
Hax-2
0 and Hax-60), 2.61-2.56 (m, 1H, H-40), 2.12-1.93 (m,
4H, H-30, H-50); EIMS (m/z): 500 [M]+, 252 [C12H14NO3S]
+,
224 [C11H14NO2S]
+, 141 [C6H5O2S]
+, 119 [C8H7O]
+, 82
[C5H8N]
+, 77 [C6H5]
+.2.6.8. N-(2,4-dimethylphenyl)-2-(5-(1-
(phenylsulfonyl)piperidin-4-yl)-1,3,4-oxadiazol-2-ylthio)
acetamide (6h)
White amorphous solid; Yield: 72%; m.p. 160–162 C; Molec-
ular formula: C23H26N4O4S2; molecular weight: 486 gmol
1;
IR (KBr, cm1): vmax: 3432 (N–H stretching), 3028 (Ar–H),
2930 (–CH2 stretching), 1618 (C‚N stretching), 1565 (Ar
C‚C stretching), 1326 (–SO2 stretching);
1H-NMR
(300 MHz, CDCl3, d/ppm): 8.62 (s, 1H, CONH), 7.77 (dd,
J= 1.8, 6.9 Hz, 2H, H-200 and H-600), 7.69 (d, J = 7.8 Hz,
1H, H-600 0), 7.60-7.55 (m, 3H, H-300 to 500), 7.53 (d,
J = 9.3 Hz, 1H, H-500 0), 6.95 (s, 1H, H-300 0), 3.95 (s, 2H, S-
CH2), 3.73 (t, J= 3.6 Hz, 2H, Heq-2
0 and Heq-60), 2.89-2.80
(m, 1H, CH2-4
0), 2.57 (dt, J= 2.7, 12.0 Hz, 2H, Hax-20 and
Hax-6
0), 2.25 (s, 3H, CH3-200 0), 2.15 (s, 3H, CH3-400 0), 2.02-
1.89 (m, 4H, H-30 and H-50); EIMS (m/z): 486 [M]+, 252
[C12H14NO3S]
+, 224 [C11H14NO2S]
+, 141 [C6H5O2S]
+, 105
[C8H9]
+, 82 [C5H8N]
+, 77 [C6H5]
+.2.6.9. N-(2,5-dimethylphenyl)-2-(5-(1-
(phenylsulfonyl)piperidin-4-yl)-1,3,4-oxadiazol-2-ylthio)
acetamide (6i)
White shiny scales; Yield: 76%; m.p. 126–128 C; Molecular
formula: C23H26N4O4S2; molecular weight: 486 gmol
1; IR
(KBr, cm1) vmax: 3437 (N–H stretching), 3018 (Ar–H),
2889 (–CH2 stretching), 1628 (C‚N stretching), 1575 (Ar
C‚C stretching), 1328 (–SO2 stretching);
1H-NMR(300 MHz, CDCl3, d /ppm): 8.61 (s, 1H, CONH), 7.74 (dd,
J= 1.5, 6.9 Hz, 2H, H-200 and H-600), 7.70 (s, 1H, H-600 0),
7.62-7.49 (m, 3H, H-300 to H-500), 7.02 (d, J= 6.3 Hz, 1H,
H-300 0), 6.86 (d, J= 7.2 Hz, 1H, H-400 0), 3.96 (s, 2H, S-
CH2), 3.73 (t, J = 3.6 Hz, 2H, Heq-2
0 and Heq-60), 2.88-2.79
(m, 1H, CH2-4
0), 2.57 (dt, J= 3.0, 12.0 Hz, 2H, Hax-20 and
Hax-6
0), 2.28 (s, 3H, CH3-200 0), 2.14 (s, 3H, CH3-500 0),
2.00–1.92 (m, 4H, H-30 and H-50); EIMS (m/z): 486 [M]+,
345 [C17H21N4O2S]
+, 252 [C12H14NO3S]
+, 224
[C11H14NO2S]
+, 141 [C6H5O2S]
+, 105 [C8H9]
+, 82
[C5H8N]
+, 77 [C6H5]
+.
2.6.10. N-(2,6-dimethylphenyl)-2-(5-(1-
(phenylsulfonyl)piperidin-4-yl)-1,3,4-oxadiazol-2-ylthio)
acetamide (6j)
White powder; Yield: 78%; m.p. 130–132 C; Molecular for-
mula: C23H26N4O4S2; molecular weight: 486 gmol
1; IR
(KBr, cm1) vmax: 3429 (N–H stretching), 3038 (Ar–H), 2931
(–CH2 stretching), 1622 (C‚N stretching), 1571 (Ar C‚C
stretching), 1320 (–SO2 stretching);
1H-NMR (300 MHz,
CDCl3, d/ppm): 8.33 (s, 1H, CONH), 7.77 (dd, J= 1.5,
6.9 Hz, 2H, H-200 and H-600), 7.61-7.50 (m, 3H, H-300 to H-
500), 7.10-7.00 (m, 3H, H-3000 to H-50 00), 3.99 (s, 2H, S-CH2),
3.74 (t, J= 3.6 Hz, 2H, Heq-2
0 and Heq-60), 2.93-2.83 (m,
1H, H-40), 2.67 (m, 2H, Hax-20 and Hax-60), 2.11 (brs, 6H,
CH3-2
00 0 and CH3-600 0), 2.04-1.94 (m, 4H, H-30 and H-50); EIMS
(m/z): 486 [M]+, 252 [C12H14NO3S]
+, 224 [C11H14NO2S]
+,
141 [C6H5O2S]
+, 105 [C8H9]
+, 82 [C5H8N]
+, 77 [C6H5]
+.
2.6.11. N-(3,4-dimethylphenyl)-2-(5-(1-
(phenylsulfonyl)piperidin-4-yl)-1,3,4-oxadiazol-2-ylthio)
acetamide (6k)
White powder; Yield: 77%; m.p. 116–118 C; Molecular for-
mula: C23H26N4O4S2; molecular weight: 486 gmol
1; IR
(KBr, cm1): vmax: 3441 (N–H stretching), 3038 (Ar–H),
1601 (C‚N stretching), 1565 (Ar C‚C stretching), 1324
(–SO2 stretching);
1H-NMR (300 MHz, CDCl3, d/ppm): 8.85
(s, 1H, CONH), 7.76 (dd, J= 1.5, 6.9 Hz, 2H, H-200 and H-
600), 7.59-7.52 (m, 3H, H-300 to H-500), 7.27 (s, 1H, H-200 0),
7.10-7.00 (m, 2H, H-50 00 and H-6000), 3.90 (s, 2H, S-CH2), 3.73
(t, J= 3.6 Hz, 2H, Heq-2
0 and Heq-60), 2.91-2.80 (m, 1H, H-
40), 2.58 (t, J= 3.6, 5.4 Hz, 2H, Hax-20 and Hax-60), 2.21 (s,
3H, CH3-3
00 0), 2.18 (s, 3H, CH3-400 0), 2.04-1.94 (m, 4H, H-30
and H-50); EIMS (m/z): 486 [M]+, 252 [C12H14NO3S]
+, 224
[C11H14NO2S]
+, 141 [C6H5O2S]
+, 105 [C8H9]
+, 82
[C5H8N]
+, 77 [C6H5]
+.
2.6.12. N-(3,5-dimethylphenyl)-2-(5-(1-
(phenylsulfonyl)piperidin-4-yl)-1,3,4-oxadiazol-2-ylthio)
acetamide (6l)
White powder; Yield: 67%; m.p. 140–145 C; Molecular
formula: C23H26N4O4S2; molecular weight: 486 gmol
1; IR
(KBr, cm1) vmax: 3440 (N–H stretching), 3031 (Ar–H), 2935
(–CH2 stretching), 1621 (C‚N stretching), 1566 (Ar C‚C
stretching), 1329 (–SO2 stretching);
1H-NMR (400 MHz,
CDCl3 d/ppm): 8.87 (s, 1H, CONH), 7.76 (dd, J= 1.6,
6.8 Hz, 2H, H-200and H-600), 7.59-7.51 (m, 3H, H-300 to H-500),
7.12 (s, 2H, H-200 0 and H-600 0), 6.73 (s, 1H, H-400 0), 3.90 (s,
2H, S-CH2), 3.75 (t, J= 3.6 Hz, 2H, Heq-2
0 and Heq-60),
2.91–2.82 (m, 1H, H-40), 2.55 (t, J= 3.6 Hz, 2H, Hax-20 and
Hax-6
0), 2.26 (s, 6H, CH3-300 0 and CH3-500 0), 2.12-1.95 (m, 4H,
Synthesis, spectral analysis and anti-bacterial study of N-substituted derivatives S619H-30 and H-50); EIMS (m/z): 486 [M]+, 252 [C12H14NO3S]
+,
224 [C11H14NO2S]
+, 141 [C6H5O2S]
+, 105 [C8H9]
+, 82
[C5H8N]
+, 77 [C6H5]
+.
2.6.13. N-benzyl-2-(5-(1-(phenylsulfonyl)piperidin-4-yl)-1,3,4-
oxadiazol-2-ylthio)acetamide (6m)
Brown color solid; Yield: 75%; m.p. 165–167 C; Molecular
formula: C22H24N4O4S2; molecular weight: 472 gmol
1; IR
(KBr, cm1) vmax: 3450 (N–H stretching), 3033 (Ar–H), 2955
(–CH2 stretching), 1598 (C‚N stretching), 1570 (Ar C‚C
stretching), 1329 (–SO2 stretching);
1H-NMR (400 MHz,
CDCl3, d/ppm): 8.03 (s, 1H, CONH), 7.76 (d, J= 7.6
Hz, 2H, H-200 and H- 600), 7.60-7.51 (m, 3H, H-300 to H-500),
7.27-7.19 (m, 5H, H-200 0 to H-600 0), 4.41 (s, 2H, H-700 0), 3.85 (s,
2H, S-CH2), 3.73 (t, J= 5.6 Hz, 2H, Heq-2
0 and Heq-60),
2.81-2.79 (m, 1H, H-40), 2.56 (dt, J= 2.0, 8.0 Hz, 2H, Hax-20
and Hax-6
0), 2.08-1.91 (m, 4H, H-30 and H-50); EIMS (m/z):
472 [M]+, 252 [C12H14NO3S]
+, 224 [C11H14NO2S]
+, 141
[C6H5O2S]
+, 91 [C7H7]
+, 82 [C5H8N]
+, 77 [C6H5]
+, 65
[C5H5]
+.
2.6.14. 2.6.14.N-phenylethyl-2-(5-(1-(phenylsulfonyl)piperidin-
4-yl)-1,3,4-oxadiazol-2-ylthio)acetamide (6n)
White powder; Yield: 79%; m.p. 155–157 C; Molecular for-
mula: C23H26N4O4S2; molecular weight: 486 gmol
1; IR
(KBr, cm1) vmax: 3448 (N–H stretching), 3040 (Ar–H), 1605
(C‚N stretching), 1567 (Ar C‚C stretching), 1325 (–SO2
stretching); 1H-NMR (300 MHz, CDCl3, d/ppm): 7.77 (d,
J= 7.6 Hz, 2H, H-200 and H-600), 7.59-7.52 (m, 3H, H-300 to
H-500), 7.12-7.10 (m, 5H, H-200 0 to H-600 0), 3.74 (s, 2H, S-
CH2), 3.08 (t, J= 2.4 Hz, 2H, H-8
00 0), 3.50 (t, J= 5.4 Hz,
2H, Heq-2
0 and Heq-60), 2.79-2.75 (m, 1H, H-40), 2.59 (t,
J= 5.4 Hz, 2H, Hax-2
0 and Hax-60), 2.13 (t, J= 2.4 Hz, 2H,
H-700 0), 2.10-1.94 (m, 4H, H-30 and H-50); EIMS (m/z): 486
[M]+, 252 [C12H14NO3S]
+, 224 [C11H14NO2S]
+, 141
[C6H5O2S]
+, 105 [C8H9]
+, 82 [C5H8N]
+, 77 [C6H5]
+.
2.7. Antibacterial activity assay
It was processed by using sterile 96-well microplates under
aseptic conditions. The basic principle is the increase in cell
number with the microbial growth in a log phase thus resulting
in an increase in the absorbance of broth medium (KaspadyS
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Scheme 1 Outline for the synthesis of N-substituted derivatives of 2-
amide. Reagents and conditions: (I) 5% Na2CO3 soln./H2O/pH= 9–1
KOH/EtOH/reﬂuxing for 6 h (IV) 2-bromoacetylbromide/H2O/5% Net al., 2009; Yang et al., 2006). Clinically isolated, Gram-
negative (S. typhi, E. coli andK. pneumonae) and Gram-positive
bacteria (B. subtilis and S. aureus) were used for screening the
synthesized compounds. The stock culture agar medium was
used to maintain the organisms. 20 lg of each sample with
appropriate dilution was pipetted out into each well. 180 lL
of overnight maintained fresh bacterial culture after suitable
dilution with fresh nutrient broth was poured in each well.
The total volume in each well was kept to 200 lL with the ini-
tial absorbance of the culture between 0.12–0.19 at 540 nm.
The incubation was processed at 37 C for 16–24 h with lid
on the micro plate. The absorbance was measured at 540 nm
using micro plate reader, before and after incubation and the
difference was noted as an index of bacterial growth. The per-
cent inhibition was calculated using the formula:
Inhibitionð%Þ ¼ ðcontrol test=controlÞ  100
where control = absorbance in control with bacterial culture
test = absorbance in test sample
Results are mean of triplicate (n= 3, ±sem). Ciproﬂoxacin
was taken as reference standard. Minimum inhibitory concen-
tration (MIC) was measured with suitable dilutions (5–30 lg/
well) and results were calculated using EZ-Fit Perrella Scien-
tiﬁc Inc. Amherst USA software, and data expressed as MIC.
2.8. Statistical Analysis
All the measurements were performed in triplicate and statisti-
cal analysis was performed by Microsoft Excel 2010. Results
are presented as mean ± sem.
3. Results and discussion
3.1. Chemistry
The N-aryl/aralkyl substituted acetamides, 6a–n were syn-
thesized according to the protocol sketched in Scheme 1.
The different N-substituted aryl/aralkyl groups are men-
tioned in Table 1. The general reaction conditions and
the structure characterization are described in experimental
section.
The given research work was an attempt to inaugurate a
new series of biologically active compounds which may beNS
OO
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O
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O
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R
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H2N R
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IV
(5-(1-(phenylsulfonyl)piperidin-4-yl)-1,3,4-oxadiazol-2-ylthio)acet-
0/stirring for 3–4 h (II) N2H4/MeOH/stirring for 5–6 h (III) CS2/
a2CO3 soln./stirring for 1 h (V) DMF/NaH/stirring for 2–3 h.
Table 1 Different N-substituted aryl/aralkyl groups.
Compd. R Compd. R Compd. R
6a 6f
OCH3
2'''4'''
6'''
6k
CH3
H3C
2'''4'''
6'''
6b 6g
2'''4'''
6'''
O
OCH3
6l
6c
CH3
2'''4'''
6'''
6h 6m
6d 6i 6n
6e 6j
S620 H. Khalid et al.helpful in drug development program. In the presented re-
search, N-aryl/aralkyl derivatives of 2-(5-(1-(phenylsulfo-
nyl)piperidin-4-yl)-1,3,4-oxadiazol-2-ylthio)acetamide were
synthesized in a series of steps and all were screened against
different Gram-negative and Gram-positive bacteria. First
ethyl 1-(phenylsulfonyl)piperidin-4-carboxylate (1) was pre-
pared by the stirring of ethyl isonipecotate (a) with benzenesul-
fonyl chloride (b) at basic pH 9–10 in aqueous media for 3–4 h
(Aziz-ur-Rehman et al., 2012; Jafarpour et al., 2011). The
product 1 was isolated after acidifying the reaction mixture.
This step is necessary for the generation of precipitates of
product present in the form of salt in the reaction mixture.
The excess of acid should be obviated as it reduces the yield.
Next step comprises the synthesis of 1-(phenylsulfonyl)piperi-
din-4-carbohydrazide (2) from compound 1 by stirring with
hydrated hydrazine in methanol for 5–6 h. Compound 2 was
then subjected to intermolecular cyclization to yield 5-[1-
(phenylsulfonyl)piperidin-4-yl]-1,3,4-oxadiazol-2-thiol (3) by
reﬂuxing with CS2/KOH for 6 h in ethanol and the product
3 was separated after acidiﬁcation. (Aziz-ur-Rehman et al.,
2012; Aziz-ur-Rehman et al., 2013). The N-aryl/aralkyl-2-bro-
moacetamides (electrophiles), 5a–n were synthesized by stirring
different aryl/aralkyl amines (4a–n) with 2-bromoacetylbro-mide in a basic medium under pH control of 9–10. The last
step includes the synthesis of target compounds 6a–n by the
reaction of 5-[1-(phenylsulfonyl)piperidin-4-yl]-1,3,4-oxa-
diazol-2-thiol (3) with electrophiles 5a–n in the presence of
DMF and NaH. Reaction completion was achieved within
2–3 h by stirring at room temperature (30 C). The products
were isolated by ﬁltration or solvent extraction (in some cases)
after the addition of cold distilled water. The structure of all
the synthesized compounds 1, 2, 3 and N-substituted deriva-
tives 6a–n was afﬁrmed by spectral data as presented in exper-
imental section.
Compound 6a was synthesized as white shiny scales with
76% yield and melting point of 126–128 C. The molecular
formula C23H26N4O4S2 was established by molecular ion peak
at m/z 486 in EI-MS and also by counting the number of pro-
tons in its 1H-NMR spectrum. The Infrared spectrum showed
absorption bands at 3437 cm1, 3018 cm1, 2889 cm1,
2553 cm1, 1628 cm1, 1575 cm1 and 1328 cm1 because of
N–H (stretching), C–H (aromatic stretching), CH2 (stretch-
ing), S–H (stretching), C‚C (aromatic stretching), C‚N
(stretching) and –SO2 (stretching of sulfonyl group) respec-
tively. The EI-MS gave characteristic peaks at m/z 224, 82
and 77 which were attributed to the loss of (phenylsulfo-
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Figure 1 Mass fragmentation pattern of N-(2,3-dimethylphenyl)-2-(5-(1-(phenylsulfonyl) piperidin-4-yl)-1,3,4-oxadiazol-2-ylthio)acet-
amide (6a).
Synthesis, spectral analysis and anti-bacterial study of N-substituted derivatives S621nyl)piperidine, piperidinyl and phenyl groups respectively. The
base peak appeared at m/z 345 relative to the N-(2,5-dimethyl-
phenyl)-2-(5-(piperidin-4-yl)-1,3,4-Oxadiazol-2-ylthio)acetam-
ide cationic fragment. In 1H-NMR spectrum, the presence of
the benzenesulfonyl ring was afﬁrmed by a doublet of doublet,
at 7.74 ppm (J = 6.9, 1.5 Hz, 2H) for H-200 and H-600 and a
multiplet, at 7.62-7.49 ppm for three protons at H-300, H-400
and H-500. One triplet at 3.73 ppm (J= 3.6 Hz) for two equa-
torial protons and one double doublet of doublet at 2.57 ppm
(J= 3.0, 12.0 Hz) for two axial protons at H-20 and H-60 and
two multiplets at 2.88-2.79 ppm due to one proton at H-40 and
2.00-1.92 ppm because of four protons at H-30 and H-50 sup-
ported the presence of piperi6dine nucleus in the molecule.
The signals resonating at 7.70 ppm as singlet for one proton
of C-600 0 and two doublets at 7.02 ppm (J= 6.3 Hz) for C-300 0
single proton and at 6.86 ppm (J= 7.2 Hz) for C-400 0 single
proton in the aromatic region along with two singlets, each
with relative intensity of three, at 2.28 ppm and 2.14 ppm for
two methyl groups at C-200 0 and C-500 0 respectively in the ali-
phatic region afﬁrmed the 2,5-dimethylaniline ring. One singlet
was also observed at 3.96 ppm for two methylene protons of
acetamide moiety attached to sulfur of the oxadiazole ring.
On the ground of all the above accumulative data, the struc-
ture of 6a was conﬁrmed as N-(2,5-dimethylphenyl)-2-(5-
(piperidin-4-yl)-1,3,4-oxadiazol-2-ylthio)acetamide. The mass
fragmentation pattern of compound 6a is clearly outlined in
Fig. 1 and also discussed as representative compound.
Likewise, the structures of other compounds were character-ized by 1H-NMR, IR and mass spectral data as described in
experimental section.
3.2. Antibacterial activity
The synthesized compounds were screened against Gram-neg-
ative and Gram-positive bacteria. The results are presented in
Table 2. The synthesized compounds were found to be moder-
ate inhibitors of the ﬁve bacterial strains employed in this
study. The % inhibition of all the compounds and MIC values
of the most active ones are shown in the Table 2. The com-
pound 6d was found to be the most active against all the bac-
terial strains i.e. S. typhi (), E. coli (), K. pneumonae (), B.
subtilis (+) and S. aureus (+) with % inhibition values of
61.53 ± 0.34, 62.20 ± 0.25, 69.60 ± 0.45, 55.66 ± 0.67 and
84.11 ± 0.24 and MIC values of 11.64 ± 0.76, 5.75 ± 0.34,
7.23 ± 0.98, 23.31 ± 0.32 and 7.71 ± 0.67 respectively with
respect to the reference standard, Ciproﬂoxacin. This com-
pound was found to be more active because of the presence
of the p-methylphenyl group attached to the nitrogen of ace-
tamidic moiety present in the molecule. Against S. typhi, B.
subtilis and S. aureus 6d was the most active; against E. coli,
all were active especially 6d and 6g; and against K. pneumonae,
6d and 6f were the most active compounds. Overall the activity
shown by the synthesized compounds was moderately good
and some of them were more active against the bacterial
strains than the reference standard as supported by their
MIC values.
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S622 H. Khalid et al.4. Conclusion
The structures of the synthesized compounds were elucidated
via spectral data, as shown in experimental section. Further
these compounds were screened for antibacterial activity to
evaluate the biological importance. The results tabulated in
Table 2, rendered the compounds as moderately active with
some exceptions. The compound 6d possessed talented activity
against all the bacterial strains with good % inhibition and
MIC values relative to the reference standard. This series of
synthesized compounds may be helpful in drug development
program for the pharmacological industries.Acknowledgement
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